Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $3.73 to $4.25
• 50-Day Range: $3.22 to $4.28
• 52-Week Range: $3.07 to $10.00
• Volume: 88,829 shs
• Average Volume: 131,839 shs
• Market Capitalization: $29.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 3% of companies evaluated by MarketBeat, and ranked 896th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Synaptogenix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Synaptogenix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.51% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 4.24.

Change versus previous month

Short interest in Synaptogenix has recently decreased by 2.04%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.70% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

10.34% of the stock of Synaptogenix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TAOX
• Previous Symbol: NASDAQ:SNPX
• CIK: 1571934
• Web: synaptogen.com
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$28.74 million
• Net Margins: -2,153.97%
• Pretax Margin: -2,153.97%
• Return on Equity: -128.51%
• Return on Assets: -97.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.98
• Quick Ratio: 19.98

Sales & Book Value

• Annual Sales: $772.50 thousand
• Price / Sales: 37.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.70 per share
• Price / Book: 2.28

Miscellaneous

• Outstanding Shares: 7,483,000
• Free Float: 7,281,000
• Market Cap: $29.03 million
• Optionable: N/A
• Beta: 1.49